Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13

Published on 10/01/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 9.50 percent to USD 10.05 billion. Amgen stock costs EUR 371.13 on October 1, 2026 after EUR 371.25, minus 0.03 percent.

Fotorealistische moderne Biotech-Produktionsanlage mit Glasfassade, Bioreaktoren und Palmen unter blauem Himmel — Amgen Inc. (ISIN US0311621009) zeigt fotorealistisch eine moderne Biotech-Anlage mit Bioreaktoren in Kalifornien, Illustration mit AI erstellt.

Amgen Inc. (ISIN US0311621009) reported positive Phase 3 results for dazodalibep in systemic Sjogren's disease on September 22, 2026, while Amgen stock was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026. The euro quote was minus 0.03 percent against the EUR 371.25 prior close, leaving the clinical update and the earnings base as the central reference points for the stock.

Dazodalibep clears its key endpoint

According to Amgen in its September 22, 2026 release, the OASIZ 301 study showed a statistically significant and clinically meaningful improvement in systemic disease activity at week 48 for adults with moderate-to-severe Sjogren's disease.

The result adds a late-stage autoimmune asset to Amgen's pipeline, but the commercial value depends on further clinical and regulatory milestones. The OASIZ 303 study is expected to complete in the fourth quarter of 2026, giving investors a defined next data point for the program.

Second-quarter revenue climbs 9.50 percent

MarketBeat reported that Amgen generated USD 10.05 billion in revenue in the second quarter of 2026, up 9.50 percent from the same quarter a year earlier. Adjusted earnings per share came in at USD 6.29, compared with a USD 5.62 consensus estimate.

The same report said Amgen maintained adjusted full-year 2026 earnings-per-share guidance of USD 22.30 to USD 23.50. The quarterly dividend was USD 2.52 per share, adding an income component while the pipeline supplies the growth debate.

Stock remains below its yearly high

Amgen's primary listing is Nasdaq, where the ticker is AMGN. The finance quote showed a market capitalization of USD 227.5 billion and a 52-week range of USD 283.00 to USD 447.03 as of September 30, 2026. The Lang & Schwarz euro quote therefore sat below the reference high in the separate US-dollar market data.

CNN lists November 2, 2026 as the next earnings date. That event will put the second-quarter revenue growth, the maintained adjusted earnings range and the pipeline read-through into one calendar checkpoint.

Euro quote edges lower

Amgen was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026 at 12:42 p.m. CEST, down 0.03 percent versus the EUR 371.25 prior close at Lang & Schwarz on September 30, 2026. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.